What precautions should be taken when administering physical therapy and spinal manipulation to patients with Graves disease, regarding thyroid control, cardiac stability, bone health, and medication side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Physical Therapy and Manipulation Considerations for Graves Disease Patients

Physical therapy and spinal manipulation should be deferred or approached with extreme caution in patients with active, untreated Graves disease until euthyroid status is achieved, with particular attention to cardiac stability, bone fragility, and muscle weakness that significantly increase injury risk.

Critical Pre-Treatment Assessment

Before initiating any physical therapy or manipulation, verify the patient's thyroid control status. Patients must achieve euthyroid status before undergoing intensive physical interventions 1. This is not merely a recommendation—it is essential for patient safety given the systemic complications of uncontrolled hyperthyroidism.

Thyroid Control Status

  • Active hyperthyroidism (untreated or inadequately controlled): Defer non-urgent physical therapy and absolutely avoid spinal manipulation
  • Achieving euthyroid status: Typically requires several weeks of antithyroid drug therapy 1
  • Stable euthyroid state: Physical therapy may proceed with modifications based on residual complications

Key Safety Concerns

1. Cardiovascular Instability

Uncontrolled Graves disease poses significant cardiac risks that make physical exertion dangerous:

  • Monitor for atrial fibrillation risk, particularly in patients over 60 years 2
  • Assess for underlying heart disease or ischemic conditions 3
  • Avoid exercises or manipulations that significantly elevate heart rate until thyroid hormones are controlled
  • Beta-blockers may be used for symptomatic control but do not eliminate underlying cardiac risk 2

2. Severe Musculoskeletal Impairment

Newly diagnosed Graves disease patients demonstrate profound muscle weakness and balance deficits 4:

  • Handgrip strength, elbow flexion/extension, and knee flexion/extension are all significantly impaired compared to healthy controls
  • Postural stability is markedly reduced in all positions
  • Functional performance tests (Timed-Up-and-Go, Repeated Chair Stand) are significantly slower
  • Free T3 levels correlate directly with degree of impairment 4

Clinical implication: These patients have substantially increased fall risk and reduced capacity to tolerate standard physical therapy protocols. Manipulation techniques requiring patient muscle stabilization are particularly hazardous.

3. Bone Fragility and Fracture Risk

Thyrotoxicosis causes significant bone loss that persists even after treatment:

  • BMD is significantly reduced in the thyrotoxic state compared to controls 5
  • Premenopausal women show clinically relevant bone loss during active disease 5
  • While BMD improves during 18 months of antithyroid drug therapy, femoral neck BMD can decrease again after stopping treatment (>0.4% per year) 5
  • Cortical porosity is increased and trabecular thickness decreased in active disease 6
  • Bone restoration occurs with treatment but takes approximately 9 months to show significant improvement in BMD and microarchitecture 6

Critical caveat: High-velocity, low-amplitude spinal manipulation carries substantial fracture risk in these patients, particularly at the femoral neck and spine. This risk persists for months even after achieving euthyroid status.

4. Medication Considerations

If the patient is on antithyroid drugs:

  • Thiamazole/carbimazole or propylthiouracil are standard treatments 1
  • Monitor for side effects in first 90 days: skin reactions (5-10%), joint/muscle pain (1-5%), hepatotoxicity 1, 7
  • Joint or muscle pain from antithyroid drugs can mimic musculoskeletal injury—distinguish medication side effects from therapy-related injury
  • Agranulocytosis is rare but serious; any fever or infection signs require immediate medical evaluation 3

Treatment Algorithm

Phase 1: Active Hyperthyroidism (Untreated or Newly Diagnosed)

Contraindications:

  • Spinal manipulation: Absolute contraindication
  • High-intensity exercise programs: Contraindicated
  • Balance training on unstable surfaces: Contraindicated

Acceptable interventions:

  • Gentle range-of-motion exercises only
  • Patient education about fall prevention
  • Defer treatment until euthyroid status achieved

Phase 2: Achieving Euthyroid Status (First 3-6 Months of Treatment)

Relative contraindications:

  • Spinal manipulation: Still contraindicated due to ongoing bone fragility
  • High-impact activities: Avoid

Modified interventions:

  • Low-intensity strengthening exercises with careful progression
  • Supervised balance training on stable surfaces
  • Cardiovascular monitoring during exercise
  • Avoid exercises requiring significant postural stability

Phase 3: Stable Euthyroid State (>6-9 Months Post-Treatment Initiation)

Proceed with caution:

  • Spinal manipulation: May consider in select patients after bone density assessment
  • Obtain DEXA scan before high-force manipulations if patient has been hyperthyroid >6 months 5, 6
  • Progress exercise intensity gradually—these patients have prolonged deconditioning
  • Continue cardiovascular monitoring in elderly patients

Phase 4: Post-Definitive Treatment (RAI or Surgery)

Patients who undergo radioactive iodine or thyroidectomy:

  • Will require lifelong levothyroxine replacement 3
  • Monitor TSH levels—both over-replacement (TSH <0.1) and under-replacement affect bone and cardiac health 2
  • Exogenous subclinical hyperthyroidism from excessive levothyroxine carries same risks as endogenous disease 2

Special Populations

Graves Orbitopathy (Thyroid Eye Disease)

  • Present in subset of Graves patients 8, 9
  • Avoid prone positioning or techniques that increase intraorbital pressure
  • Coordinate with ophthalmology regarding activity restrictions
  • RAI treatment can worsen eye disease in 15-20% of patients 3, 8

Elderly Patients (>60 years)

  • Higher risk for atrial fibrillation and cardiovascular mortality 2
  • More pronounced bone loss and fracture risk
  • Lower threshold for deferring manipulation and high-intensity therapy

Common Pitfalls to Avoid

  1. Assuming euthyroid status based on patient report alone—verify recent thyroid function tests (TSH, free T4, free T3)

  2. Mistaking antithyroid drug side effects for therapy-related injury—joint/muscle pain occurs in 1-5% on medication 1

  3. Underestimating fall risk—balance and postural stability are severely compromised even in newly diagnosed patients 4

  4. Proceeding with manipulation based on age alone—young patients with Graves disease have significant bone loss 5

  5. Failing to recognize treatment failure—approximately 50% of patients on antithyroid drugs will relapse 3, 7, 10; ongoing symptoms may indicate inadequate thyroid control, not musculoskeletal pathology

  6. Ignoring medication adherence—most "resistant" cases are actually non-adherence 1; verify compliance before attributing symptoms to therapy

Documentation Requirements

Before proceeding with physical therapy or manipulation:

  • Recent TSH, free T4, free T3 levels (within 4-6 weeks)
  • Current medication regimen and duration
  • Cardiac evaluation if over 60 or symptomatic
  • DEXA scan if hyperthyroid >6 months or post-menopausal
  • Clearance from endocrinologist for moderate-to-high intensity interventions

The fundamental principle: achieving and maintaining euthyroid status takes absolute priority over musculoskeletal treatment goals. Morbidity and mortality risks from cardiovascular events and fractures in uncontrolled Graves disease far outweigh any benefits from premature physical interventions 2, 3, 4, 5.

References

Guideline

treatment of adult graves' disease.

Annales d'endocrinologie, 2018

Research

Muscle Performance and Postural Stability Are Reduced in Patients with Newly Diagnosed Graves' Disease.

Thyroid : official journal of the American Thyroid Association, 2019

Research

Changes in bone density and microarchitecture following treatment of Graves' disease and the effects of vitamin D supplementation. A randomized clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2024

Research

Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.

The Journal of clinical endocrinology and metabolism, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.